hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06382207 id: HM20029298 briefTitle: Effectiveness of the Eko Digital Stethoscope in Capturing Infant ECGs overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-12 date: 2024-12 date: 2024-04-24 date: 2024-04-24 name: Virginia Commonwealth University class: OTHER name: Eko Devices, Inc. briefSummary: When a newborn is diagnosed with tachyarrhythmia, they are generally started on medical therapies, most commonly a beta-blocker, while being observed in an inpatient setting. In most academic institutions, current practice is to provide parental teaching on use of a stethoscope to auscultate their child when there is suspicion for distress, in addition to requiring cardiopulmonary resuscitation (CPR) classes. Fortunately, newer technologies have emerged that allow for capture of cardiac rhythm that may provide a buffer between the infant and the emergency room. conditions: Tachyarrhythmia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This proof-of-concept study will enroll infants, defined as individuals \<1 year of age. It will assess the feasibility and effectiveness of a physician and parent/caregiver in using the Eko DUO and CORE 500 to capture ECGs in patients \<10 kg in a clinic and home setting. primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: Eko Duo electronic stethoscope name: CORE 500 electronic stethoscope measure: Number and proportion of good-quality ECG recordings taken by physicians, for DUO and for CORE 500 measure: Number and proportion of good-quality ECG recordings taken by parents/caregivers, with a physician present in the exam room using the CORE 500 measure: Number and proportion of good-quality ECG recordings taken by parents/caregivers, with a physician absent from the exam room, for CORE 500 measure: Number and proportion of good-quality ECG recordings taken by parents/caregivers, at home, for CORE 500 only sex: ALL maximumAge: 1 Year stdAges: CHILD facility: Virginia Commonwealth University city: Richmond state: Virginia zip: 23298 country: United States lat: 37.55376 lon: -77.46026 hasResults: False
nctId: NCT06382194 id: STUDY00014522 id: 1R21AG076362-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R21AG076362-01 briefTitle: Decision Making Tool for Firearm Storage overallStatus: RECRUITING date: 2024-04-01 date: 2024-06-30 date: 2024-07-31 date: 2024-04-24 date: 2024-04-24 name: University of Washington class: OTHER name: National Institute on Aging (NIA) briefSummary: This is a one-arm pilot study testing the feasibility and acceptability of a decision aid about safe firearm storage. conditions: Dementia, Mild conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 66 type: ESTIMATED name: Decision aid measure: Firearm storage (adapted from the National Firearm Survey) measure: Low-Literacy Decisional Conflict Scale measure: Knowledge Questionnaire measure: Feasibility of intervention delivery measure: Acceptability of Intervention Measure sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of Washington status: RECRUITING city: Seattle state: Washington zip: 98104 country: United States name: Rachel Ross, MPH role: CONTACT phone: 509-596-1438 email: rross4@uw.edu name: Elizabeth A Phelan, MD role: PRINCIPAL_INVESTIGATOR name: Laura Prater, PhD role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06382181 id: 2023- ENFPOD-2621979 id: Silvia Corchón Arreche type: OTHER domain: University of Valencia id: Omar Cauli type: OTHER domain: University of Valencia briefTitle: A Multimodal Intervention for Community-dwelling Individuals With Unwanted Loneliness overallStatus: COMPLETED date: 2023-04-01 date: 2023-07-01 date: 2023-07-31 date: 2024-04-24 date: 2024-04-24 name: University of Valencia class: OTHER briefSummary: The absence of social relationships negatively affects physical, psychological, and social health. In other words, it alters people's quality of life and makes active aging difficult. The investigators have designed a study to reduce unwanted loneliness in people over 65 living in the community through multiple interventions (music therapy, health education, and physical exercise). conditions: Loneliness conditions: Mental Health Disorder studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants were assigned to three groups in parallel for the duration of the study primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 20 type: ACTUAL name: Music therapy for community-dwelling individuals with unwanted loneliness name: Health education for community-dwelling individuals with unwanted loneliness name: Physical exercise for community-dwelling individuals with unwanted loneliness measure: Score on the Jong Gierveld Loneliness Scale measure: Score on Goldberg Anxiety and Depression Scale sex: ALL minimumAge: 60 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Valencia city: Valencia zip: 46010 country: Spain lat: 39.46975 lon: -0.37739 facility: Vanessa Ibáñez del Valle city: Valencia zip: 46010 country: Spain lat: 39.46975 lon: -0.37739 hasResults: False
nctId: NCT06382155 id: 111-210 briefTitle: A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2026-06 date: 2036-12 date: 2024-04-24 date: 2024-04-24 name: BioMarin Pharmaceutical class: INDUSTRY briefSummary: The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS). conditions: Idiopathic Short Stature studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Vosoritide Injection name: Human Growth Hormone name: Placebo measure: Change from baseline in Annualized Growth Velocity (AGV) measure: Change from baseline in height measure: Change from baseline in height Z-score measure: Incidence of treatment-emergent adverse events measure: Change from baseline in AGV Z-score (average stature reference) measure: Change from baseline in height measure: Change from baseline in height Z score measure: Change from baseline at prespecified timepoints in urine cyclic guanine monophosphate (cGMP) measure: Change from baseline at pre-specified timepoints in serum collagen X marker (CXM) measure: Change from baseline in bone age minus chronological age at pre-specified timepoints measure: Change from baseline in total body (less head) bone mineral density (BMD) Z-score measure: Change from baseline in lumbar spine BMD Z-score measure: Change from baseline in total body (less head) bone mineral content (BMC) measure: Change from baseline in lumbar spine BMC measure: Maximum concentration (Cmax) of vosoritide in plasma measure: Area under the plasma vosoritide concentration time-curve from time 0 to infinity (AUC0-∞) measure: Area under the plasma vosoritide concentration time-curve from time 0 to the last measurable concentration (AUC0-t) measure: Elimination half-life of vosoritide (t½) measure: Apparent clearance of vosoritide measure: Apparent volume of distribution of vosoritide based upon the terminal phase (Vz/F) measure: Time vosoritide is present at maximum concentration (Tmax) sex: ALL minimumAge: 3 Years maximumAge: 10 Years stdAges: CHILD hasResults: False
nctId: NCT06382142 id: BL-B01D1-307 briefTitle: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-24 date: 2024-04-24 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-B01D1 in patients with unresectable locally advanced or metastatic Triple-Negative breast cancer after taxane failure. conditions: Triple-Negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 436 type: ESTIMATED name: BL-B01D1 name: Eribulin name: Vinorelbine name: Gemcitabine name: Capecitabine measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Treatment Emergent Adverse Event (TEAE) measure: Anti-drug antibody (ADA) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fudan University Shanghai Cancer Center city: Shanghai state: Shanghai country: China name: Jiong Wu role: CONTACT name: Jiong Wu role: PRINCIPAL_INVESTIGATOR name: Jian Zhang role: PRINCIPAL_INVESTIGATOR lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06382129 id: BL-B01D1-302 briefTitle: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-24 date: 2024-04-24 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic EGFR wild-type non-small cell lung cancer after failure of anti-PD-1/PD-L1 monoclonal antibodies and platinum-based chemotherapy. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 558 type: ESTIMATED name: BL-B01D1 name: Docetaxel measure: Overall survival (OS) measure: Progression-free survival (PFS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Treatment Emergent Adverse Event (TEAE) measure: Anti-drug antibody (ADA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences city: Beijing state: Beijing country: China name: Jie Wang role: CONTACT lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06382116 id: BL-B01D1-301 briefTitle: A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-24 date: 2024-04-24 name: Sichuan Baili Pharmaceutical Co., Ltd. class: INDUSTRY name: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. briefSummary: This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in patients with locally advanced or metastatic non-squamous non-small cell lung cancer with EGFR-sensitive mutations after EGFR-TKI failure. conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 428 type: ESTIMATED name: BL-B01D1 name: Pemetrexed+Cisplatin or Carboplatin measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Duration of Response (DOR) measure: Treatment Emergent Adverse Event (TEAE) measure: Anti-drug antibody (ADA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen University Cancer Center city: Guangzhou state: Guangdong country: China name: Li Zhang role: CONTACT lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06382103 id: B2024-108R briefTitle: Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy overallStatus: NOT_YET_RECRUITING date: 2024-04-20 date: 2025-05-20 date: 2026-05-20 date: 2024-04-24 date: 2024-04-24 name: Shanghai Zhongshan Hospital class: OTHER briefSummary: Blood samples will be tested to identify circulating tumor DNA and plasma protein levels to potentially improve prediction of long term prognosis and guide treatment options of patients with hepatocellular carcinoma underwent surgical resection. conditions: Hepatocellular Carcinoma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: ctDNA monitoring name: Plasma proteomic analysis measure: Correlation between ctDNA level and recurrence-free survival (RFS) measure: Correlation between specific plasma protein expression level and recurrence-free survival (RFS) measure: Correlation between tumor mutation numbers and recurrence-free survival (RFS) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: 180 Fenglin Road city: Shanghai zip: 200032 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06382090 id: PamukkaleU-SBE-BB-01 briefTitle: Premenstrual Syndrome and Laughter Yoga overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2024-05-24 date: 2025-05-24 date: 2024-04-24 date: 2024-04-24 name: Pamukkale University class: OTHER briefSummary: In addition to physical and emotional effects, premenstrual syndrome can negatively affect the participation in classes, school success, social activities and family relationships of young adolescents in high school. Many non-pharmacological treatments have been found to improve premenstrual syndromes in adolescents. Laughter yoga, one of these methods, is a practice consisting of deep breathing exercises and laughter exercises. Laughter yoga has been studied in different sample groups (elderly people, nurses, dialysis patients, etc.) and positive results have been obtained. In this study, the effect of laughter yoga on premenstrual symptoms in adolescents will be examined. conditions: Premenstrual Syndrome conditions: Laughter studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Two groups: comparative experiment and control primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 68 type: ESTIMATED name: Laughter yoga measure: Premenstrual Symptom Scale sex: FEMALE minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06382077 id: CPSP5502 briefTitle: Chronic Post Surgical Pain-Cardiac acronym: CPSP-Cardiac overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2025-04-25 date: 2025-10-25 date: 2024-04-24 date: 2024-04-24 name: Ondokuz Mayıs University class: OTHER briefSummary: The CPSP-Cardiac is a large, multi-center, observational study with the aim to investigate the incidence of chronic pain in the 3rd month postoperatively in cardiac surgery and its affecting factors. conditions: Chronic Post-surgical Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1176 type: ESTIMATED measure: The incidence of chronic postsurgical pain measure: Postoperative opioid consumption in the first 24 hours measure: Postoperative pain scores measure: The incidences of postoperative nausea and vomiting measure: The number of patients with side effects and complications measure: Time to extubation measure: Length of stay in the intensive care unit measure: Length of stay in the hospital measure: Chronic pain status at 3 and 6 months measure: Psychological assessment measure: Quality of life assessment measure: Postoperative complications at 3 and 6 months sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ondokuz Mayis University city: Samsun state: Atakum zip: 55139 country: Turkey lat: 41.27976 lon: 36.3361 facility: Istanbul University city: Istanbul country: Turkey name: Zerrin Sungur role: CONTACT lat: 41.01384 lon: 28.94966 facility: Marmara University city: Istanbul country: Turkey name: Alper Kararmaz role: CONTACT lat: 41.01384 lon: 28.94966 facility: Burhan Dost city: Samsun zip: 55270 country: Turkey name: BURHAN DOST role: CONTACT phone: 05327042493 email: burhandost@hotmail.com lat: 41.27976 lon: 36.3361 hasResults: False
nctId: NCT06382064 id: 2024H0089 briefTitle: Evaluation of Wear Experience With One Week Reusable Contact Lenses in Habitual Two Week Reusable Lens Wearers overallStatus: ACTIVE_NOT_RECRUITING date: 2024-04-16 date: 2024-09 date: 2025-05 date: 2024-04-24 date: 2024-04-24 name: Ohio State University class: OTHER briefSummary: This open-label study is of current Acuvue® Oasys® wearers (2 - week replacement, reusable lenses) who are satisfied with their current lenses. Subjects will be refit into one week reusable contact lenses and will wear lenses for approximately 2 weeks. Subjects will return for vision and lens fit assessments and will complete surveys about their wear experience. conditions: Myopia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Subjects will be fit into Acuvue Oasys contact lenses at the first visit to wear for 2 weeks. Subjects will then be fit into PRECISION7 lenses at the second visit to wear for 2 weeks. primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Biweekly replacement contact lenses name: One week replacement contact lenses measure: Subjective assessment of lens wear experience sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Ohio State University College of Optometry city: Columbus state: Ohio zip: 43210 country: United States lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06382051 id: CAIN457ACA06 briefTitle: Modifying PEST for Psoriatic Arthritis Screening acronym: ScreenX overallStatus: NOT_YET_RECRUITING date: 2024-06-28 date: 2025-04-30 date: 2025-04-30 date: 2024-04-24 date: 2024-04-24 name: Novartis Pharmaceuticals class: INDUSTRY briefSummary: The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Patients will be enrolled in the study for up to 66 days and will be asked to fill-out a PsA screening questionnaire at their first dermatologist visit. Patients screening positive for PsA will have a second visit with a rheumatologist where a full PsA diagnosis assessment will be performed. A remote 'end of study' (EOS) visit will be conducted by the dermatologist to document the patient's biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) treatment choice and status. conditions: Plaque Psoriasis conditions: Psoriatic Arthritis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: SCREENING masking: NONE count: 502 type: ESTIMATED name: PEST Screening group measure: Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs measure: Proportion of patients scoring negative on PEST and positive on PEST+2 with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist measure: Proportion of patients with a confirmed new PsA diagnosis or suspicion of PsA by a rheumatologist measure: Proportion of patients with a false positive score between each group measure: Description of the baseline characteristics of the positive screening score and negative screening score patients for both PEST and PEST+2 tests measure: Patient acceptability/user experience of the PEST+2 questionnaire measure: Administration of dermatologist quantitative surveys measure: Qualitative interview with selected dermatologists measure: Intervention Appropriateness Measure (IAM) sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06382038 id: HZKY-PJ-2024-19 briefTitle: Smart Technology Facilitated Patient-centered Care for Patients With Pulmonary Thromboembolism acronym: SmaPE overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-10-31 date: 2026-10-31 date: 2024-04-24 date: 2024-04-24 name: Navy General Hospital, Beijing class: OTHER briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of pulmonary thromboembolism (PTE) on the long-term outcome of PTE patients, in order to enhance clinical practice and establish a foundation of evidence for managing patients with PTE. conditions: Venous Thromboembolism conditions: Pulmonary Thromboembolisms conditions: Clinical Decision Support Systems conditions: Digital Health studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 3078 type: ESTIMATED name: mobile venous thromboembolism application (mVTEA) measure: VTE-related composite event measure: Patient satisfaction with anticoagulant treatment measure: Generic quality of life measure: Recurrent VTE measure: Chronic thromboembolic pulmonary hypertension (CTEPH) measure: Major bleeding measure: VTE-related hospitalization measure: Death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sixth Medical Center of Chinese PLA General Hospital city: Beijing state: Beijing zip: 100048 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06382025 id: Alkinstorybook briefTitle: Preoperative Information With Storybook for Pediatric Anesthesia overallStatus: COMPLETED date: 2018-03-09 date: 2020-02-20 date: 2020-05-29 date: 2024-04-24 date: 2024-04-24 name: Trakya University class: OTHER briefSummary: Impacts of non-pharmacologic methods that help patients get prepared cognitively for processes of surgery and anesthesia on pediatric surgery patients' preoperational stress levels and anxiety levels had been examined in the scope of this comprehensive research project. In this project, a goal-oriented 8-9 minutes animation cartoon that is informative and educational had been developed, and pediatric surgery patients had been asked to watch this animation during preoperative period. conditions: Animation, Cartoons, Preoperative Care, Anesthesia, Pediatric studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: SINGLE whoMasked: INVESTIGATOR count: 168 type: ACTUAL name: showing cartoons -storybook name: showing cartoons - standard measure: preoperative anxiety scale measure: State-trait anxiety inventory (STAI FORM TX-1, TX-2) for parents measure: Children's Hospital of Eastern Ontario Pain (CHEOP) Scale measure: Pediatric Anesthesia Emergence Delirium (PAED) scale sex: ALL minimumAge: 5 Years maximumAge: 10 Years stdAges: CHILD facility: Trakya University city: Edirne state: Edi̇rne zip: 22030 country: Turkey lat: 41.67719 lon: 26.55597 hasResults: False